Hypoparathyroidism Market Will Grow at Highest Pace Owing to Rising Prevalence of Hypoparathyroidism Disorders

Hypoparathyroidism Market Will Grow at Highest Pace Owing to Rising Prevalence of Hypoparathyroidism Disorders

The hypoparathyroidism market comprises drugs and therapies used in the treatment of hypoparathyroidism disorders, which involve inadequate or low levels of parathyroid hormone (PTH) in the body. Hypoparathyroidism disorders can be congenital due to genetic mutations or acquired after thyroid or parathyroid gland surgeries. Key drugs available in the market are calcium supplements, calcitriol, and cinacalcet hydrochloride. Calcium supplements are administered to reduce symptoms of hypocalcemia by maintaining adequate calcium levels. Calcitriol, a form of vitamin D, helps in the absorption of calcium from the intestines. Cinacalcet hydrochloride is a calcium-sensing receptor agonist that reduces serum calcium levels. These drugs provide effective management of symptoms and help improve the quality of life of patients. The rising prevalence of autoimmune disorders and benign thyroid tumors resulting in hypoparathyroidism after surgery is a major factor driving the demand for treatment drugs and therapies.

The hypoparathyroidism market is estimated to be valued at USD 731.1 Mn in 2024 and is expected to reach USD 1213.4 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

Key Takeaways
Key players operating in the hypoparathyroidism market are Shire, F. Hoffmann-La Roche Ltd, Entera Bio Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc.

The increasing prevalence of hypoparathyroidism disorders globally is expected to boost the demand for treatment drugs and therapies. As per recent studies, around 7 in 10,000 individuals are affected by hypoparathyroidism worldwide.

Hypoparathyroidism Market Growth in formulations such as controlled-release medications and improvement in surgical techniques are enhancing treatment outcomes and patient compliance with drugs. Development of recombinant PTH drugs for long-term maintenance therapy can further expand the treatment landscape.

Market Trends
Increasing Adoption of Combination Therapy
Combination of calcitriol and calcium supplements is becoming a widely adopted first-line therapeutic approach for hypoparathyroidism. Adding cinacalcet to standard therapy is also proven to provide additional symptomatic benefits.

Rise of Novel Drug Delivery Systems
Drug developers are focusing on novel drug delivery systems such as controlled-release formulations and auto-injectors to improve convenience and ensure adherence to long-term maintenance therapy regimens.

Market Opportunities
Development of Recombinant PTH Drugs

Recombinant human PTH drugs for long-term treatment can offer enhanced efficacy over current standard of care drugs and expand treatment options.

Growing Patient Pool in Asia Pacific
Countries in Asia Pacific are witnessing a surge in autoimmune disorders causative of hypoparathyroidism at a rapid pace. This represents major opportunities for players to strengthen presence and product offerings.

Impact of COVID-19 on Hypoparathyroidism Market Growth
The COVID-19 pandemic has significantly impacted the growth of the global hypoparathyroidism market. During the initial outbreak, research activities and clinical trials regarding hypoparathyroidism management were put on hold to focus resources on COVID-19 patients. This led to a decline in new clinical trial patient enrollment as well as interruptions in drug production and supply chains. However, with the launch of vaccination programs and relaxation of lockdowns in 2021, research activities are gradually recovering.

The restricted movement during lockdowns made it difficult for patients to visit hospitals and clinics for routine checkups and management of hypoparathyroidism symptoms. This can have long term health implications if symptoms remain uncontrolled for an extended period. Teleconsultations helped to some extent but many patients in remote locations had limited or no access to such services. The development of innovative home-based monitoring devices and management plans assume significance in the present scenario to address accessibility issues.

As the pandemic situation stabilizes, focus on innovative drug development and new treatment paradigms for hypoparathyroidism is expected to continue. Collaborations between research organizations, healthcare providers, and pharma companies will play a key role in addressing current challenges and driving future growth opportunities. Adherence to strict safety protocols will be critical to ensure uninterrupted clinical research activities.

Geographical Regions with High Market Concentration
North America currently dominates the global hypoparathyroidism market, primarily due to the presence of major players, sophisticated healthcare infrastructure, and high disease awareness levels. The United States contributes significantly to the North American market due to the large patient population and favorable reimbursement policies.

Europe is the second largest regional market stimulated by rising government spending on healthcare. Germany holds a substantial share of the European market owing to the growing geriatric demographic susceptible to hypoparathyroidism.

Asia Pacific is envisioned as the fastest growing regional market driven by improving access to diagnosis and treatment in highly populated countries like China and India. Rising medical tourism and collaborations with developed markets are further bolstering growth opportunities across Asia Pacific.

Fastest Growing Regional Market - Asia Pacific
The Asia Pacific region is expected to witness the highest growth in the global hypoparathyroidism market over the forecast period. This is attributed to rising healthcare expenditure, increasing focus on rare disease diagnosis and management, and growing patient access to advanced treatment options through public and private healthcare initiatives.

The presence of a huge patient population base along with the willingness to adopt innovative treatment modalities at lower costs drives market growth across Asia Pacific countries. Additional factors such as growing collaboration between international research bodies and pharmaceutical companies for clinical trials and data generation from Asia Pacific countries will aid market expansion. Rising medical tourism across South Asian countries like India further complements the market growth dynamics.

Get More Insights On- Hypoparathyroidism Market

Get This Report in Japanese Language: 副甲状腺機能低下症市場

Get This Report in Korean Language: 저갑상선기능저하증 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.

(https://www.linkedin.com/in/ravina-pandya-1a3984191)